GlassScriptPhysician profile
John J Rozanski
NPI 1669437760
$3,026.17
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $118 · 2021: $507 · 2022: $460 · 2023: $1,006 · 2024: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,692.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $772.77 | 2021-2024 | Farxiga, Brilinta, Lokelma |
| Boston Scientific Corporation | $597.55 | 2022-2024 | Watchman Flx, Watchman Access System |
| Heartflow, INC. | $444.55 | 2023-2024 | Ffrct |
| Abbott Laboratories | $370.27 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $253.59 | 2019-2023 | |
| Cvrx, INC. | $147.81 | 2023 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $129.89 | 2023 | Camzyos |
| Amarin Pharma, INC. | $128.08 | 2019 | |
| Shockwave Medical, INC | $125.10 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cardiva Medical, INC. | $38.10 | 2023 | Cardiva Vascade 6/7f Vcs |
| Merck Sharp & Dohme LLC | $18.46 | 2024 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rozanski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.